Both local and systemic inflammation are reduced upon GSK-J4 treatment, which establishing a link between the H3K27me3 demethylases’ activity with GM-CSF as well as the collagen induced arthritis, suggested a potential application of targeting epigenetic modifiers in RA patients. This evidence concerns the gene CSF2 and arthritic joint disease.